Key facts
- Notable investors include ClavystBio.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Eyexora
- ·The full record, as it builds
Funding rounds
No funding rounds for Eyexora are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Eyexora
Developer of integrated ophthalmology platforms designed to accelerate the development and delivery of eye care therapies and devices. The company centralizes scientific, clinical, regulatory, and commercial capabilities within a hub-and-spoke structure, advances a diversified pipeline through specialized subsidiaries, and collaborates with global clinician-scientists and research institutes, enabling ophthalmology-focused organizations to reduce development risk, improve operational efficiency, and scale the impact of innovative treatments for patients worldwide.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2025
- Website
- eyexora.com/
- Ownership
- Privately Held (backing)
Eyexora doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Eyexora shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Eyexora in its N-PORT filings yet. We sweep new filings monthly.